Krystal Biotech, Inc.
Company Stats
- Market Cap
- $9.8B
- as of Sep 30, 2026
- Shares Outstanding
- 29.6M
- Free Float
- 65.5%
Income Statement
- Revenue
- $389.1M
- Operating Income
- $161.3M
- Net Income
- $204.8M
- EBITDA
- $167.0M
- FCF Margin, 3Y Avg
- -36.3%
- FCF Margin, Worst Year
- -198.4%
Cash Flow
- Free Cash Flow
- $188.9M
- FCF Yield
- 1.9%
- Owner FCF Yield
- 1.4%
Balance Sheet
- Cash & Equivalents
- $496.3M
Returns & Capital
- SBC, 3Y Avg
- $47.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $389.1M | $188.9M | 48.5% |
| FY2024 | $290.5M | $119.2M | 41.0% |
| FY2023 | $50.7M | -$100.6M | -198.4% |
| FY2022 | $0 | -$153.5M | — |
| FY2021 | $0 | -$116.3M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back